Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries
STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients.
Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation
The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.
Q&A: Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair
How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview.
FDA approves Abbott’s TriClip TEER device for tricuspid regurgitation
Less than two months after an FDA advisory panel voted in favor of approval, the transcatheter edge-to-edge repair system can now be sold and marketed in the United States.
Data registries have been a huge success for U.S. structural heart programs
ACC/STS National Cardiovascular Data Registry metrics reporting for TAVR is important for marketing and care quality, explains Patricia Keegan, NP, with the Emory Heart and Vascular Center.

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries

STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients.

April 26, 2024

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

April 26, 2024

2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.

Q&A: Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair

How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview.

April 18, 2024

Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

FDA approves Abbott’s TriClip TEER device for tricuspid regurgitation

Less than two months after an FDA advisory panel voted in favor of approval, the transcatheter edge-to-edge repair system can now be sold and marketed in the United States.

April 2, 2024

Video of Patricia Keegan, NP, Emory, explains value of the ACC TVT NCDR registry for TAVR and why it is important from both a quality monitoring standpoint and for attracting patients to your program.

Data registries have been a huge success for U.S. structural heart programs

ACC/STS National Cardiovascular Data Registry metrics reporting for TAVR is important for marketing and care quality, explains Patricia Keegan, NP, with the Emory Heart and Vascular Center.

February 16, 2024

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

FDA advisory panel votes in favor of Abbott’s TriClip device for tricuspid regurgitation

After hours of discussion, the panel determined that the benefits of using the TriClip G4 TEER system to treat TR outweigh any potential risks.

February 14, 2024

FDA panel to consider Abbott’s TriClip device for tricuspid regurgitation

The panel's decision will be based on data from the TRILUMINATE study, which was ultimately positive for Abbott, but did lead to certain questions about patient outcomes.

February 13, 2024

FDA approved the first transcatheter tricuspid valve (TTVR) replacement device in February 2024, the EVOQUE system from Edwards Lifesciences. The Evoque is the first transcatheter tricuspid valve approved by the FDA. The Evoke the first transcatheter tricuspid cleared in the United States.

Edwards makes history, receives FDA approval for transcatheter tricuspid valve replacement device

The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation.

February 2, 2024

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."